



Applicants: Ron S. Israeli, et al.
Serial No.: 10/751,346
Filed: January 2, 2004
Page 11

THIRD SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following documents which are listed on the attached Form PTO-1449 (**EXHIBIT A**). A copy of the disclosures listed below as items 1-3 are attached hereto as **EXHIBITS B-D** respectively:

1. Silver, D.A. et al., Prostate-Specific Membrane Antigen Expression in Normal and Malignant Human Tissues, Clin. Cancer Res. (1997) 3:81-85;
2. Chang, S.S. et al., Five Different Anti-Prostate-Specific membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature, Cancer Res. (1999) 59:3192-3198; and
3. Lerner, R.A., Antibodies of Predetermined Specificity in Biology and Medicine, (1984) Advances in Immunology 36:1-44.

This Third Supplemental Information Disclosure Statement supplements the Information Disclosure Statements Previously filed by applicants on September 8, 2005; June 14, 2004; and December 14, 2004 in connection with the above-identified application.

This Third Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(c) and a check for ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) is enclosed herewith.

Applicants: Ron S. Israeli, et al.
Serial No.: 10/751,346
Filed: January 2, 2004
Page 12


If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.


No fee, other than the total enclosed fee of \$690.00, including a \$180.00 Information Disclosure Statement fee and a \$510.00 fee for a three-month extension of time, is deemed necessary in connection with the filing of this Amendment and Third Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
	5/9/06
John P. White Reg. No. 28,678	Date



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

1

Application Number

10/751,346

Filing Date

January 2, 2004

First Named Inventor

Ron S. Israeli

Art Unit

1647

Examiner Name

Lei Yao

Attorney Docket Number

1769/41426-FA-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Silver, D.A. et al., Prostate-Specific Membrane Antigen Expression in Normal and Malignant Human Tissues, Clin. Cancer Res. (1997) 3:81-85	
	2	Chang, S.S. et al., Five Different Anti-Prostate-Specific membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature, Cancer Res. (1999) 59:3192-3198	
	3	Lerner, R.A. Antibodies of Predetermined Specificity in Biology & Medicine (1984) Adv. in Immunol. 36:1-44	
	4		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Exhibit A

U.S. Serial No. 10/751,346

Filed: January 2, 2004